Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
18. September 2024 07:00 ET
|
Engrail Therapeutics, Inc.
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
08. August 2024 07:00 ET
|
Engrail Therapeutics, Inc.
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and
Saira Ramasastry to Board of Directors